Aegros' chief executive, Damian Thornton, a 35‑year industry veteran brought in after a financial and board restructure, said the company’s 2025 capital raise was pivotal in addressing prior debt issues and unlocking completion of the facility without further government funding beyond R&D tax incentives.
Aegros completes Australia’s second large scale plasma fractionation plant
July 8, 2026 Latest NewsAustralian BiotechBioPharma
Latest Video
New Stories
-
The regulator that deleted the truth from its answers now wants to police the media
October 1, 2026 - - Latest News -
By the TGA's own test, the Health Minister's press releases are advertising
October 1, 2026 - - Latest News -
Eczema patients who don't respond to steroids get subsidised access to ointment
October 1, 2026 - - Latest News -
Vitrafy takes its frozen platelet push to America's Midwest
September 30, 2026 - - Australian Biotech -
Paradigm Biopharmaceuticals enters voluntary administration after Phase 3 setback
September 30, 2026 - - Australian Biotech -
FDA fast tracks Telix scan that could spare men prostate biopsies
September 30, 2026 - - Australian Biotech -
Australian broadcast personality reveals the scars shingles left behind
September 30, 2026 - - Latest News
